Investigating how a protein affects drug resistance in multiple myeloma
C/EBPβ in bone marrow stromal cell-mediated drug resistance of multiple myeloma
This study is looking at how the environment in your bone marrow affects why some treatments for multiple myeloma don't work as well as they should, focusing on a protein that might help explain this resistance, with the hope of finding new ways to improve treatment for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-10916383 on NIH RePORTER |
What this research studies
This research focuses on understanding how the bone marrow environment contributes to drug resistance in multiple myeloma, a type of blood cancer. It specifically examines the role of a protein called C/EBPβ, which may regulate genes involved in this resistance. By studying the interactions between bone marrow stromal cells and cancer cells, the research aims to uncover the epigenetic mechanisms that lead to treatment failure. Patients may benefit from insights that could lead to new therapeutic strategies to overcome drug resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are experiencing drug resistance.
Not a fit: Patients with other types of cancers or those not affected by multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with multiple myeloma by overcoming drug resistance.
How similar studies have performed: Other research has shown that targeting epigenetic mechanisms can be effective in addressing drug resistance in various cancers, suggesting potential for success in this approach.
Where this research is happening
Morgantown, United States
- West Virginia University — Morgantown, United States (Active)
Researchers
- Principal investigator: Hu, Gangqing — West Virginia University
- Study coordinator: Hu, Gangqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.